Association between the FAS/FASL polymorphisms and gastric cancer risk: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 3, 2012, Pages 945-951

  Tian, Jing ^a,b   Pan, Feng ^a   Li, Jing ^a,b   Ma, Yan ^a,b   Cen, Han ^a,b   Pan, Hai Feng ^a,b   Pan, Yue Yin ^a   Ye, Dong Qing ^a,b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Anhui Provincial Laboratory of Population Health and Major Disease Screening and Diagnosis   (China)

Author keywords

Analysis; FAS; FASL; Gastric cancer; Meta; Polymorphism

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ARTICLE; GENETIC PREDISPOSITION; GENETICS; HUMAN; META ANALYSIS; PROMOTER REGION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH TUMOR;

ANTIGENS, CD95; FAS LIGAND PROTEIN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS; STOMACH NEOPLASMS;

EID: 84871696286     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.3.945     Document Type: Article

References (48)

1. Ashkenazi A, Dixit VM (1999). Apoptosis control by death and decoy receptors. Curr Opin Cell Biol, 11, 255-60.
2. Budihardjo I, Oliver H, Lutter M, et al (1999). Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol, 15, 269-90.
3. Chappell DB, Restifo NP (1998). T cell-tumor cell: a fatal interaction? Cancer Immunol Immunother, 47, 65-71.
4. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29.
5. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
6. Duell EJ, Travier N, Lujan-Barroso L, et al (2011). Alcohol consumption and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Am J Clin Nutr, 94, 1266-75.
7. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
8. Faul F, Erdfelder E, Buchner A, et al (2009). Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods, 41, 1149-60.
9. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
10. Green DR, Droin N, Pinkoski M (2003). Activation-induced cell death in T cells. Immunol Rev, 193, 70-81.
11. Griffith TS, Brunner T, Fletcher SM, et al (1995). Fas ligand-induced apoptosis as a mechanism of immune privilege. Science, 270, 1189-92.
12. Gryko M, Guzíńska-Ustymowicz K, Pryczynicz A, et al (2011). Correlation between Fas and FasL proteins expression in normal gastric mucosa and gastric cancer. Folia Histochem Cytobiol, 49, 142-7.
13. Hajra KM, Liu JR (2004). Apoptosome dysfunction in human cancer. Apoptosis, 9, 691-704.
14. Hartgrink HH, Jansen EP, van Grieken NC, et al (2009). Gastric cancer. Lancet, 374, 477-90.
15. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
16. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
17. Hirschhorn JN, Lohmueller K, Byrne E, et al (2002). A comprehensive review of genetic association studies. Genet Med, 4, 45-61.
18. Hsu PI, Lu PJ, Wang EM, et al (2008). Polymorphisms of death pathway genes FAS and FASL and risk of premalignant gastric lesions. Anticancer Res, 28, 97-103.
19. Huang QR, Morris D, Manolios N (1997). Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol, 34, 577-82.
20. Ikehara SK, Ikehara Y, Matsuo K, et al (2006). A polymorphism of C-to-T substitution at -31 IL1B is associated with the risk of advanced gastric adenocarcinoma in a Japanese population. J Hum Genet, 51, 927-33.
21. Itoh N, Yonehara S, Ishii A, et al (1991). The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 66, 233-43.
22. Knottnerus JA (1987). Subject selection in hospital-based case-control studies. J Chronic Dis, 40, 183-7.
23. Kupcinskas J, Wex T, Bornschein J, et al (2011). Lack of association between gene polymorphisms of Angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians. BMC Med Genet, 12, 112.
24. Liu L, Wu C, Wang Y, et al (2011). Association of candidate genetic variations with gastric cardia adenocarcinoma in Chinese population: a multiple interaction analysis. Carcinogenesis, 32, 336-42.
25. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
26. Nagata S, Golstein P (1994). The Fas death factor. Science, 267, 1449-56.
27. Nicholson DW, Thornberry NA (1997). Caspases: killer proteases. Trends Biochem Sci, 22, 299-306.
28. Nomura AM, Wilkens LR, Henderson BE, et al (2012). The association of cigarette smoking with gastric cancer: the multiethnic cohort study. Cancer Causes Control, 23, 51-8.
29. Oehm A, Behrmann I, Falk W, et al (1992). Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem, 267, 10709-15.
30. Reed JC (2000). Mechanisms of apoptosis. Am J Pathol, 157, 1415-30.
31. Reichmann E (2002). The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol, 12, 309-15.
32. Sibley K, Rollinson S, Allan JM, et al (2003). Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res, 63, 4327-30.
33. Sivachandran N, Dawson CW, Young LS, et al (2012). Contributions of the Epstein-Barr Virus EBNA1 Protein to Gastric Carcinoma. J Virol, 86, 60-8.
34. Strand S, Hofmann WJ, Hug H, et al (1996). Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med, 2, 1361-6.
35. Suda T, Takahashi T, Golstein P, et al (1993). Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell, 75, 1169-78.
36. Sun T, Zhou Y, Li H, et al (2005). FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med, 202, 967-74.
37. Takahama Y, Yamada Y, Emoto K, et al (2002). The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer, 5, 61-8.
38. Thompson CB (1995). Apoptosis in the pathogenesis and treatment of disease. Science, 267, 1456-62.
39. Viard-Leveugle I, Veyrenc S, French LE, et al (2003). Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. J Pathol, 201, 268-77.
40. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.
41. Wang M, Wu D, Tan M, et al (2009). FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China. Biochem Genet, 47, 59-68.
42. Wu J, Metz C, Xu X, et al (2003). A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol, 170, 132-8.
43. Yang CS (2000). Vitamin nutrition and gastroesophageal cancer. J Nutr, 130, S338-9.
44. Yang KC, Chu A, Liao CS, et al (2006). Evaluation of the role of H pylori infection in pathogenesis of gastric cancer by immunoblot assay. World J Gastroenterol, 12, 7029-32.
45. Yang WG, Chen CB, Wang ZX, et al (2011). A case-control study on the relationship between salt intake and salty taste and risk of gastric cancer. World J Gastroenterol, 17, 2049-53.
46. Zhang W, Li C, Wang J, He C (2011). Functional polymorphisms in FAS/FASL system contribute to the risk of occurrence but not progression of gastric cardiac adenocarcinoma. Hepatogastroenterology, 59. doi: 10.5754/hge11300.
47. Zhou RM, Wang N, Chen ZF, et al (2010). Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. J Gastroenterol Hepatol, 25, 555-61.
48. Zou YF, Wang F, Feng XL, et al (2011). Association of NFKB1-94ins/delATTG promoter polymorphism with susceptibility to autoimmune and inflammatory diseases: a meta-analysis. Tissue Antigens, 77, 9-17.